STING1 and Miyoshi myopathy: Since PD-L1/PD-1 interactions could potentially restrain anticancer immunity induced by STING activation, we evaluated if adding an immune checkpoint inhibitor blocking PD-1 function to the bortezomib and STING agonist treatment could enhance the anti-MM efficacy in the Vκ*MYC-bearing mice.